scholarly journals EXPRESSÃO DE BAFF (B-CELL ACTIVATING FACTOR) E RESPOSTA IMUNE TH2 É MAIOR EM PACIENTES QUE EVOLUEM COM RECIDIVA NA HEMOFILIA A ADQUIRIDA

2021 ◽  
Vol 43 ◽  
pp. S224-S225
Author(s):  
JO Frade-Guanaes ◽  
AP Racanelli ◽  
LH Siqueira ◽  
C Costa-Lima ◽  
SS Medina ◽  
...  
Keyword(s):  
B Cell ◽  
B Cell Activating Factor ◽  
Hemofilia A

scholarly journals B-cell activating factor BAFF as a novel alert marker for the immunological risk stratification after kidney transplantation

2021 ◽  
Author(s):  
Antonia Margarete Schuster ◽  
N. Miesgang ◽  
L. Steines ◽  
C. Bach ◽  
B. Banas ◽  
...  
Keyword(s):  
Kidney Transplantation ◽  
B Cell ◽  
Graft Function ◽  
Risk Profile ◽  
Kidney Transplant Recipients ◽  
Post Transplantation ◽  
Antibody Mediated Rejection ◽  
B Cell Activating Factor ◽  
Medium Risk ◽  
Patients At Risk

AbstractThe B cell activating factor BAFF has gained importance in the context of kidney transplantation due to its role in B cell survival. Studies have shown that BAFF correlates with an increased incidence of antibody-mediated rejection and the development of donor-specific antibodies. In this study, we analyzed a defined cohort of kidney transplant recipients who were treated with standardized immunosuppressive regimens according to their immunological risk profile. The aim was to add BAFF as an awareness marker in the course after transplantation to consider patient’s individual immunological risk profile. Included patients were transplanted between 2016 and 2018. Baseline data, graft function, the occurrence of rejection episodes, signs of microvascular infiltration, and DSA kinetics were recorded over 3 years. BAFF levels were determined 14 d, 3 and 12 months post transplantation. Although no difference in graft function could be observed, medium-risk patients showed a clear dynamic in their BAFF levels with low levels shortly after transplantation and an increase in values of 123% over the course of 1 year. Patients with high BAFF values were more susceptible to rejection, especially antibody-mediated rejection and displayed intensified microvascular inflammation; the combination of high BAFF + DSA puts patients at risk. The changing BAFF kinetics of the medium risk group as well as the increased occurrence of rejections at high BAFF values enables BAFF to be seen as an awareness factor. To compensate the changing immunological risk, a switch from a weaker induction therapy to an intensified maintenance therapy is required.

Increased Serum B Cell-Activating Factor (BAFF) Level in Children with Atopic Dermatitis

2008 ◽  
Vol 121 (2) ◽  
pp. S120-S120
Author(s):  
H JEE ◽  
B CHOI ◽  
K KIM ◽  
M SOHN ◽  
G JANG ◽  
...  
Keyword(s):  
Atopic Dermatitis ◽  
B Cell ◽  
B Cell Activating Factor ◽  
Baff Level

scholarly journals Retraction Note: Interleukin 17 acts in synergy with B cell–activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus

2014 ◽  
Vol 15 (9) ◽  
pp. 894-894
Author(s):  
Agnès Doreau ◽  
Alexandre Belot ◽  
Jérémy Bastid ◽  
Benjamin Riche ◽  
Marie-Claude Trescol-Biemont ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
B Cell ◽  
Lupus Erythematosus ◽  
Cell Biology ◽  
Interleukin 17 ◽  
Systemic Lupus ◽  
B Cell Activating Factor

B Cell-activating Factor and its Targeted Therapy in Autoimmune Diseases

2021 ◽  
Author(s):  
Yidan Zhang ◽  
Jie Tian ◽  
Fan Xiao ◽  
Leting Zheng ◽  
Xiaoxia Zhu ◽  
...  
Keyword(s):  
Targeted Therapy ◽  
Autoimmune Diseases ◽  
B Cell ◽  
B Cell Activating Factor

CVID-Associated B Cell Activating Factor Receptor Variants Change Receptor Oligomerization, Ligand Binding and Signaling Responses

2021 ◽  
Author(s):  
Violeta Block ◽  
Eirini Sevdali ◽  
Mike Recher ◽  
Hassan Abolhassani ◽  
Lennart Hammarstrom ◽  
...  
Keyword(s):  
B Cells ◽  
B Cell ◽  
Cell Receptor ◽  
Ectodomain Shedding ◽  
Cellular Functions ◽  
Single Nucleotide Variants ◽  
B Cell Activating Factor ◽  
Human B Cells ◽  
Receptor Component ◽  
Primary Amino

Abstract Purpose B cell activating factor (BAFF) binding to BAFF-receptor(BAFFR) activates essential cellular functions required forthe survival of mature, human B cells. Thus,deletion ofthe BAFFR gene blocks the development of B cells at the transition from immature to mature B cells resulting in B lymphopenia and hypogammaglobulinemia. In addition to complete BAFFR deficiency, single nucleotide variants changing the primary amino acid sequence of BAFFR gene exist. Some of these variants were foundin patients suffering from immunodeficiency, autoimmunity, or B cell lymphomas. However, it remains unclearto which extent such variants disturb the activity of BAFFR. Methods Since individual differences and genetic/environmental modifiers change the expression and activity of BAFFR, we developed a cellular system that allows the unbiased analysis of BAFFR variants P21R, A52T, G64V, Dup92-95, P146S, and H159Y regarding oligomerization, signaling, and ectodomain shedding.Results Here we show that several of these variants impair BAFFR oligomerization, direct interactions between BAFFR and the B cell receptor component CD79B, BAFFR ectodomain shedding and the activation of AKT and ERK1/2. Conclusion All of these variants are pathogenic and have the potential to contribute to the development of primary antibody deficiencies, autoimmunity and lymphoma, but they most likely do not cause B lymphopenia and agammaglobulinemia like complete BAFFR deficiency.

scholarly journals B Cell Activating Factor, Renal Allograft Antibody-Mediated Rejection, and Long-Term Outcome

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Haiyan Xu ◽  
Xiaozhou He ◽  
Renfang Xu
Keyword(s):  
B Cell ◽  
Renal Allograft ◽  
Delayed Diagnosis ◽  
Clinical Manifestations ◽  
Direct Proof ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Antibody Mediated Rejection ◽  
B Cell Activating Factor

Antibody-mediated rejection (ABMR) of renal allograft lacks typical phenotypes and clinical manifestations, always resulting in delayed diagnosis and treatment. It has been considered to be an elemental factor influencing the improvement of the long-term outcome of renal allograft. The B cell activating factor (BAFF) signal plays a fundamental function in the process of antibody-mediated immune response. Data from recipients and the nonhuman primate ABMR model suggest that the BAFF signal participates in the ABMR of renal allograft, while there are objections. The challenges in the diagnosis of ABMR, different study population, and details of research may explain the discrepancy. Large quantities of dynamic, credible data of BAFF ligands and their association with renal allograft pathological characteristics would constitute a direct proof of the role of BAFF in the progression of renal allograft ABMR.

Sign in / Sign up

Export Citation Format

Share Document